The treatment of Rett Syndrome (RTT), a rare, genetic neurological disorder affecting young children that leads to severe impairments, is continuing to evolve. The first therapy was approved in March 2023, and with several investigational assets on the horizon, there is a critical need to educate both community-based clinicians and Centers of Excellence on this change to the standard of care.   Read More

Asthma, a serious chronic lung disease, affects 26.8 million adults and 4.5 million children in the U.S. according to the American Lung Association.1 Research on the pathophysiology of type 2 inflammation has brought new targeted therapies to market that may make a significant difference for patients affected by uncontrolled moderate-to-severe asthma.2 While these innovative biologics play a significant role in treating disease, integration by healthcare practitioners (HCPs) remains inconsistent due to barriers in provider knowledge and confidence.   Read More

Medical Experts Provide Guidance for Educational Design BOSTON, July 16, 2024 – PlatformQ Health is excited to announce the formation of the Medlive Advisory Board led by key opinion leaders Read More

Triple-negative breast cancer (TNBC) remains difficult to treat, and disproportionately affects women of color. To address these challenges, PlatformQ Health joined together with TOUCH: The Black Breast Cancer Alliance and the National Breast Cancer Foundation to develop a tethered educational program to empower patients in treatment decision making and to help facilitate better patient-clinical communication through sharing of real-world outcomes.  Read More

New platform to empower patients, caregivers, physicians, and healthcare partners BOSTON, May 28, 2024 – PlatformQ Health is pleased to announce Medlive, a new platform that embodies the company’s mission Read More

Early treatment of homozygous familial hypercholesterolemia (HoFH) improves outcomes for children and reduces the risk of progressive atherosclerotic cardiovascular disease. Unfortunately, the disease often goes undetected until it is in the advanced stages.  Read More

For people with moderate-to-severe asthma, personalization of biologic agents is warranted based on factors such as biomarkers and comorbidities. PlatformQ Health and the Asthma and Allergy Foundation of America (AAFA) conducted a CME-certified, case based, expert panel discussion that featured a live Q&A session with leading faculty from the Asthma Center at Cincinnati Children's Hospital Medical Center and the Division of Allergy and Immunology at Northwestern University's Feinberg School of Medicine, as well as AAFA's public health manager. Read More

PlatformQ Health is known for its outcomes-driven education. At this year’s European Conference on Rare Diseases, we co-presented two posters highlighting outcomes and lessons learned from recent programming.   Read More

The first FDA-approved gene therapy for pediatric patients with Duchenne muscular dystrophy (DMD) is now available. This is a genetic disorder that presents as progressive muscle degeneration and weakness. Read More

As we look forward to the holiday season, we are filled with gratitude to all our incredible partners. Read More

PlatformQ Health, the National Organization for Rare Disorders (NORD), the International Fibrodyslpasia Ossificans Progressiva Association (IFOPA) Read More

The Asthma and Allergy Foundation of America (AAFA) and PlatformQ Health have extended their long-standing collaboration for another three years to continue bringing trusted digital education to those affected by asthma and related conditions. Read More